I recently sat down with senior biotechnology analyst Karen Andersen to discuss Gilead Sciences (GILD). A few weeks ago, we raised our fair value estimate for Gilead to $71 per share, based on positive clinical trial results and a lower cost of equity assumption. While Gilead has only a narrow moat, the moat trend is positive. If all goes well with its drug pipeline, Gilead could cross the threshold into wide-moat territory soon.
Matt Coffina, editor of Morningstar StockInvestor: Gilead’s historical strength has been in HIV drugs. How has the company's portfolio of HIV drugs evolved, and where are we now in terms of growth potential and patent protection?
To view this article, become a Morningstar Basic member.
Matthew Coffina has a position in the following securities mentioned above: JNJ. Find out about Morningstar’s editorial policies.